1
|
Zenkov RG, Vlasova OA, Maksimova VP, Fetisov TI, Karpechenko NY, Ektova LV, Eremina VA, Popova VG, Usalka OG, Lesovaya EA, Belitsky GA, Yakubovskaya MG, Kirsanov KI. Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269. Molecules 2021; 26:molecules26237329. [PMID: 34885910 PMCID: PMC8658795 DOI: 10.3390/molecules26237329] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 11/24/2021] [Accepted: 11/30/2021] [Indexed: 11/16/2022] Open
Abstract
Novel indolocarbazole derivatives named LCS were synthesized by our research group. Two of them were selected as the most active anticancer agents in vivo. We studied the mechanisms of anticancer activity in accordance with the previously described effects of indolocarbazoles. Cytotoxicity was estimated by MTT assay. We analyzed LCS-DNA interactions by circular dichroism in cholesteric liquid crystals and fluorescent indicator displacement assay. The effect on the activity of topoisomerases I and II was studied by DNA relaxation assay. Expression of interferon signaling target genes was estimated by RT-PCR. Chromatin remodeling was analyzed–the effect on histone H1 localization and reactivation of epigenetically silenced genes. LCS-induced change in the expression of a wide gene set was counted by means of PCR array. Our study revealed the cytotoxic activity of the compounds against 11 cancer cell lines and it was higher than in immortalized cells. Both compounds bind DNA; binding constants were estimated—LCS-1208 demonstrated higher affinity than LCS-1269; it was shown that LCS-1208 intercalates into DNA that is typical for rebeccamycin derivatives. LCS-1208 also inhibits topoisomerases I and IIα. Being a strong intercalator and topoisomerase inhibitor, LCS-1208 upregulates the expression of interferon-induced genes. In view of LCSs binding to DNA we analyzed their influence on chromatin stability and revealed that LCS-1269 displaces histone H1. Our analysis of chromatin remodeling also included a wide set of epigenetic experiments in which LCS-1269 demonstrated complex epigenetic activity. Finally, we revealed that the antitumor effect of the compounds is based not only on binding to DNA and chromatin remodeling but also on alternative mechanisms. Both compounds induce expression changes in genes involved in neoplastic transformation and target genes of the signaling pathways in cancer cells. Despite of being structurally similar, each compound has unique biological activities. The effects of LCS-1208 are associated with intercalation. The mechanisms of LCS-1269 include influence on higher levels such as chromatin remodeling and epigenetic effects.
Collapse
Affiliation(s)
- Roman G. Zenkov
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
- Correspondence:
| | - Olga A. Vlasova
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
| | - Varvara P. Maksimova
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
| | - Timur I. Fetisov
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
| | - Natalia Y. Karpechenko
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
| | - Lidiya V. Ektova
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
| | - Vera A. Eremina
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
| | - Valeriia G. Popova
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
- Faculty of Biotechnology and Industrial Ecology, Mendeleev University of Chemical Technology of Russia, 9 Miusskaya Ploshchad, 125047 Moscow, Russia
| | - Olga G. Usalka
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
- International School “Medicine of the Future”, I.M. Sechenov First Moscow State Medical University, 8-2 Trubetskaya St., 119991 Moscow, Russia
| | - Ekaterina A. Lesovaya
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
- Department of Oncology, I.P. Pavlov Ryazan State Medical University, 9 Vysokovoltnaya St., 390026 Ryazan, Russia
| | - Gennady A. Belitsky
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
| | - Marianna G. Yakubovskaya
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
| | - Kirill I. Kirsanov
- N. N. Blokhin Russian Cancer Research Center, 24 Kashirskoe Shosse, 115478 Moscow, Russia; (O.A.V.); (V.P.M.); (T.I.F.); (N.Y.K.); (L.V.E.); (V.A.E.); (V.G.P.); (O.G.U.); (E.A.L.); (G.A.B.); (M.G.Y.); (K.I.K.)
- Institute of Medicine, RUDN University, 6 Miklukho-Maklaya St., 117198 Moscow, Russia
| |
Collapse
|
2
|
Spolitak T, Ballou DP. Evidence for catalytic intermediates involved in generating the chromopyrrolic acid scaffold of rebeccamycin by RebO and RebD. Arch Biochem Biophys 2015; 573:111-9. [DOI: 10.1016/j.abb.2015.03.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Revised: 03/23/2015] [Accepted: 03/24/2015] [Indexed: 10/23/2022]
|
3
|
Dezhenkova LG, Tsvetkov VB, Shtil AA. Topoisomerase I and II inhibitors: chemical structure, mechanisms of action and role in cancer chemotherapy. RUSSIAN CHEMICAL REVIEWS 2014. [DOI: 10.1070/rc2014v083n01abeh004363] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
4
|
Laha JK, Zhang X, Qiao L, Liu M, Chatterjee S, Robinson S, Kosik KS, Cuny GD. Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors. Bioorg Med Chem Lett 2011; 21:2098-101. [PMID: 21353545 DOI: 10.1016/j.bmcl.2011.01.140] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2010] [Revised: 01/27/2011] [Accepted: 01/31/2011] [Indexed: 11/30/2022]
Abstract
Cdk5/p25 has emerged as a principle therapeutic target for numerous acute and chronic neurodegenerative diseases, including Alzheimer's disease. A structure-activity relationship study of 2,4-diaminothiazole inhibitors revealed that increased Cdk5/p25 inhibitory activity could be accomplished by incorporating pyridines on the 2-amino group and addition of substituents to the 2- or 3-position of the phenyl ketone moiety. Interpretation of the SAR results for many of the analogs was aided through in silico docking with Cdk5/p25 and calculating protein hydrations sites using WaterMap. Finally, improved in vitro mouse microsomal stability was also achieved.
Collapse
Affiliation(s)
- Joydev K Laha
- Laboratory for Drug Discovery in Neurodegeneration, Harvard NeuroDiscovery Center, Brigham & Women's Hospital and Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Deslandes S, Chassaing S, Delfourne E. Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition. Mar Drugs 2009; 7:754-86. [PMID: 20098609 PMCID: PMC2810226 DOI: 10.3390/md7040754] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2009] [Revised: 11/18/2009] [Accepted: 11/27/2009] [Indexed: 12/15/2022] Open
Abstract
Granulatimide and isogranulatimide are alkaloids obtained from marine sources which have been shown to inhibit cell-cycle G2-checkpoint, targeting more particularly checkpoint 1 kinase (Chk1). At a structural level, they possess a characteristic pyrrolocarbazole framework also shared by the well-known rebeccamycin and staurosporine microbial metabolites which have been described to inhibit topoisomerase I and diverse kinases, respectively. This review reports precisely on the synthesis and kinase inhibitory activities of pyrrolocarbazole-based analogues of granulatimide.
Collapse
Affiliation(s)
- Sébastien Deslandes
- Laboratoire de Synthèse et Physicochimie de Molécules d’Intérêt Biologique, UMR CNRS 5068, Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cédex 9, France; E-Mails:
(S.D.);
(S.C.)
| | - Stefan Chassaing
- Laboratoire de Synthèse et Physicochimie de Molécules d’Intérêt Biologique, UMR CNRS 5068, Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cédex 9, France; E-Mails:
(S.D.);
(S.C.)
| | - Evelyne Delfourne
- Laboratoire de Synthèse et Physicochimie de Molécules d’Intérêt Biologique, UMR CNRS 5068, Université Paul Sabatier, 118 route de Narbonne, 31062 Toulouse Cédex 9, France; E-Mails:
(S.D.);
(S.C.)
| |
Collapse
|
6
|
Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, Trouplin V, Bianchi J, Aushev VN, Camonis J, Calabrese A, Borg-Capra C, Sippl W, Collura V, Boissy G, Rain JC, Guedat P, Delansorne R, Daviet L. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8:2286-95. [PMID: 19671755 DOI: 10.1158/1535-7163.mct-09-0097] [Citation(s) in RCA: 258] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Deregulation of the ubiquitin/proteasome system has been implicated in the pathogenesis of many human diseases, including cancer. Ubiquitin-specific proteases (USP) are cysteine proteases involved in the deubiquitination of protein substrates. Functional connections between USP7 and essential viral proteins and oncogenic pathways, such as the p53/Mdm2 and phosphatidylinositol 3-kinase/protein kinase B networks, strongly suggest that the targeting of USP7 with small-molecule inhibitors may be useful for the treatment of cancers and viral diseases. Using high-throughput screening, we have discovered HBX 41,108, a small-molecule compound that inhibits USP7 deubiquitinating activity with an IC(50) in the submicromolar range. Kinetics data indicate an uncompetitive reversible inhibition mechanism. HBX 41,108 was shown to affect USP7-mediated p53 deubiquitination in vitro and in cells. As RNA interference-mediated USP7 silencing in cancer cells, HBX 41,108 treatment stabilized p53, activated the transcription of a p53 target gene without inducing genotoxic stress, and inhibited cancer cell growth. Finally, HBX 41,108 induced p53-dependent apoptosis as shown in p53 wild-type and null isogenic cancer cell lines. We thus report the identification of the first lead-like inhibitor against USP7, providing a structural basis for the development of new anticancer drugs.
Collapse
|
7
|
A TOPological Sub-structural Molecular Design (TOPS-MODE)-QSAR approach for modeling the antiproliferative activity against murine leukemia tumor cell line (L1210). Bioorg Med Chem 2009; 17:537-47. [DOI: 10.1016/j.bmc.2008.11.084] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2008] [Revised: 11/25/2008] [Accepted: 11/29/2008] [Indexed: 11/22/2022]
|
8
|
Saíz-Urra L, Pérez-Castillo Y, Pérez González M, Molina Ruiz R, Cordeiro M, Rodríguez-Borges J, García-Mera X. Theoretical Prediction of Antiproliferative Activity against Murine Leukemia Tumor Cell Line (L1210). 3D-Morse Descriptor and its Application in Computational Chemistry. ACTA ACUST UNITED AC 2008. [DOI: 10.1002/qsar.200860060] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
9
|
Marminon C, Anizon F, Moreau P, Pfeiffer B, Pierré A, Golsteyn RM, Peixoto P, Hildebrand MP, David-Cordonnier MH, Lozach O, Meijer L, Prudhomme M. Rebeccamycin derivatives as dual DNA-damaging agents and potent checkpoint kinase 1 inhibitors. Mol Pharmacol 2008; 74:1620-9. [PMID: 18768386 DOI: 10.1124/mol.108.049346] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Rebeccamycin is an indolocarbazole class inhibitor of topoisomerase I. In the course of structure-activity relationship studies on rebeccamycin derivatives, we have synthesized analogs with the sugar moiety attached to either one or both indole nitrogens. Some analogs, especially those with substitutions at the 6' position of the carbohydrate moiety, exhibit potent inhibitory activity toward checkpoint kinase 1 (Chk1), a kinase that has a major role in the G(2)/M checkpoint in response to DNA damage. Some of these compounds retained a genotoxic activity either through intercalation into the DNA and/or by topoisomerase I-mediated DNA cleavage. We explored the structure-activity relationship between these compounds and their multiple targets. These rebeccamycin derivatives represent a novel class of potential antitumor agents that have a dual effect and might selectively induce the death of cancer cells.
Collapse
Affiliation(s)
- Christelle Marminon
- Laboratoire SEESIB, Université Blaise Pascal, Unité Mixte de Recherche 6504 du Centre National de la Recherche Scientifique, Aubière, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Sánchez C, Méndez C, Salas JA. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Nat Prod Rep 2006; 23:1007-45. [PMID: 17119643 DOI: 10.1039/b601930g] [Citation(s) in RCA: 309] [Impact Index Per Article: 17.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The indolocarbazole family of natural products, including the biosynthetically related bisindolylmaleimides, is reviewed (with 316 references cited). The isolation of indolocarbazoles from natural sources and the biosynthesis of this class of compounds are thoroughly reviewed, including recent developments in molecular genetics, enzymology and metabolic engineering. The biological activities and underlying modes of action displayed by natural and synthetic indolocarbazoles is also presented, with an emphasis on the development of analogs that have entered clinical trials for its future use against cancer or other diseases.
Collapse
Affiliation(s)
- César Sánchez
- Departamento de Biología Funcional & Instituto Universitario de Oncología del Principado de Asturias (I.U.O.P.A.), Universidad de Oviedo, 33006, Oviedo, Spain
| | | | | |
Collapse
|
11
|
Zhang C, Albermann C, Fu X, Peters NR, Chisholm JD, Zhang G, Gilbert EJ, Wang PG, Van Vranken DL, Thorson JS. RebG- and RebM-Catalyzed Indolocarbazole Diversification. Chembiochem 2006; 7:795-804. [PMID: 16575939 DOI: 10.1002/cbic.200500504] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Rebeccamycin and staurosporine represent two broad classes of indolocarbazole glycoside natural products with antitumor properties. Based upon previous sequence annotation and in vivo studies, rebG encodes for the rebeccamycin N-glucosyltransferase, and rebM for the requisite 4'-O-methyltransferase. In the current study, an efficient in vivo biotransformation system for RebG was established in both Streptomyces lividans and Escherichia coli. Bioconversion experiments revealed RebG to glucosylate a set of indolocarbazole surrogates, the products of which could be further modified by in vitro RebM-catalyzed 4'-O-methylation. Both RebG and RebM displayed substrate promiscuity, and evidence for a remarkable lack of RebG regioselectivity in the presence of asymmetric substrates is also provided. In the context of the created indolocarbazole analogues, cytotoxicity assays also highlight the importance of 4'-O-methylation for their biological activity.
Collapse
Affiliation(s)
- Changsheng Zhang
- Laboratory for Biosynthetic Chemistry, Pharmaceutical Sciences Division, School of Pharmacy, 777 Highland Avenue, Madison, WI 53705, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Nishizawa T, Grüschow S, Jayamaha DHE, Nishizawa-Harada C, Sherman DH. Enzymatic Assembly of the Bis-Indole Core of Rebeccamycin. J Am Chem Soc 2005; 128:724-5. [PMID: 16417354 DOI: 10.1021/ja056749x] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Rebeccamycin is a member of the family of indolocarbazole antibiotics with broad spectrum antitumor activity. The indolocarbazole framework is derived from two molecules of tryptophan, but very little is known about the enzymes involved in rebeccamycin biosynthesis. Here, we show that RebD is responsible for all catalytic steps forming the central pyrrole ring of chlorochromopyrrolic acid from two molecules of chloroindolepyruvic acid. This transformation does not require any additional cofactors and constitutes the first step of bis-indole formation in the biosynthesis of rebeccamycin.
Collapse
Affiliation(s)
- Tomoyasu Nishizawa
- Department of Medicinal Chemistry, Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA
| | | | | | | | | |
Collapse
|
13
|
Langenhan JM, Griffith BR, Thorson JS. Neoglycorandomization and chemoenzymatic glycorandomization: two complementary tools for natural product diversification. JOURNAL OF NATURAL PRODUCTS 2005; 68:1696-711. [PMID: 16309329 DOI: 10.1021/np0502084] [Citation(s) in RCA: 118] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
In an effort to explore the contribution of the sugar constituents of pharmaceutically relevant glycosylated natural products, chemists have developed glycosylation methods that are amenable to the generation of libraries of analogues with a broad array of glycosidic attachments. Recently, two complementary glycorandomization strategies have been described, namely, neoglycorandomization, a chemical approach based on a one-step sugar ligation reaction that does not require any prior sugar protection or activation, and chemoenzymatic glycorandomization, a biocatalytic approach that relies on the substrate promiscuity of enzymes to activate and attach sugars to natural products. Since both methods require reducing sugars, this review first highlights recent advances in monosaccharide generation and then follows with an overview of recent progress in the development of neoglycorandomization and chemoenzymatic glycorandomization.
Collapse
Affiliation(s)
- Joseph M Langenhan
- Laboratory for Biosynthetic Chemistry, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, Wisconsin 53705, USA
| | | | | |
Collapse
|
14
|
Messaoudi S, Anizon F, Léonce S, Pierré A, Pfeiffer B, Prudhomme M. Synthesis and cytotoxicities of 7-aza rebeccamycin analogues bearing various substituents on the sugar moiety, on the imide nitrogen and on the carbazole framework. Eur J Med Chem 2005; 40:961-71. [PMID: 15907347 DOI: 10.1016/j.ejmech.2005.04.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2005] [Revised: 04/07/2005] [Accepted: 04/07/2005] [Indexed: 10/25/2022]
Abstract
The synthesis of a family of rebeccamycin analogues in which one indole unit has been replaced by a 7-azaindole moiety is described. Substitutions have been carried out on the imide nitrogen, on the carbazole framework and on the sugar part. Compounds with a lactam upper heterocycle have also been prepared. The cytotoxicities of the newly synthesized compounds toward four tumor cell lines, one murine leukemia (L1210) and three human tumor cell lines (prostate carcinoma DU145, colon carcinoma HT29, and non-small cell lung carcinoma A549) have been evaluated and compared to those of rebeccamycin and parent non-aza and aza compounds.
Collapse
Affiliation(s)
- Samir Messaoudi
- Université Blaise Pascal, Synthèse et Etude de Systèmes à Intérêt Biologique, UMR 6504 du CNRS, 63177 Aubière, France
| | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Nishizawa T, Aldrich CC, Sherman DH. Molecular analysis of the rebeccamycin L-amino acid oxidase from Lechevalieria aerocolonigenes ATCC 39243. J Bacteriol 2005; 187:2084-92. [PMID: 15743957 PMCID: PMC1064027 DOI: 10.1128/jb.187.6.2084-2092.2005] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2004] [Accepted: 12/14/2004] [Indexed: 11/20/2022] Open
Abstract
Rebeccamycin, a member of the tryptophan-derived indolocarbazole family, is produced by Lechevalieria aerocolonigenes ATCC 39243. The biosynthetic pathway that specifies biosynthesis of this important metabolite is comprised of 11 genes spanning 18 kb of DNA. A presumed early enzyme involved in elaboration of the rebeccamycin aglycone is encoded by rebO, located at the left-hand region of the reb gene cluster. The deduced protein product, RebO (51.9 kDa), is an L-amino acid oxidase (L-AAO) that has 27% identity to an L-AAO from Scomber japonicus (animal, mackerel) and is a member of the family of FAD-dependent oxidase enzymes. In order to study the biochemical properties of this key enzyme, the rebO gene was overexpressed and purified from Escherichia coli. Biochemical characterization showed that RebO is dimeric, with a molecular mass of approximately 101 kDa. Further analysis revealed that the enzyme contains a noncovalently bound FAD cofactor and is reoxidized at the expense of molecular oxygen by producing one molecule of hydrogen peroxide. Based on kinetic studies, RebO shows significant preference for 7-chloro-L-tryptophan, suggesting its likely role as the natural early pathway substrate. Furthermore, the native RebO enzyme has evident, albeit limited, flexibility as shown by bioconversion studies with unnatural substrates. This work provides the first analysis of a structural enzyme involved in construction of this important class of indolocarbazole natural products.
Collapse
Affiliation(s)
- Tomoyasu Nishizawa
- Life Science Institute, Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109-2216, USA
| | | | | |
Collapse
|
17
|
Laronze M, Boisbrun M, Léonce S, Pfeiffer B, Renard P, Lozach O, Meijer L, Lansiaux A, Bailly C, Sapi J, Laronze JY. Synthesis and anticancer activity of new pyrrolocarbazoles and pyrrolo-β-carbolines. Bioorg Med Chem 2005; 13:2263-83. [PMID: 15830466 DOI: 10.1016/j.bmc.2004.12.045] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
'Bended' 1, 3 or 'linear' 2 pyrrolidino-fused (aza)carbazoles were prepared and screened towards a few cancer-related targets. Whereas 'bended' derivatives 1 and 3 proved to be weakly toxic, several members of the 'linear' family strongly interact with DNA, especially derivative 28a.
Collapse
Affiliation(s)
- M Laronze
- CNRS FRE 2715 'Isolement, Structure, Transformations et Synthèse de Produits Naturels', IFR 53, Faculté de Pharmacie, 51 Rue Cognacq Jay, 51096 Reims cedex, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Moreau P, Holbeck S, Prudhomme M, Sausville EA. Cytotoxicities of three rebeccamycin derivatives in the National Cancer Institute screening of 60 human tumor cell lines. Anticancer Drugs 2005; 16:145-50. [PMID: 15655411 DOI: 10.1097/00001813-200502000-00005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Among the biologically active indolocarbazoles, rebeccamycin, a microbial metabolite produced by Saccharothrix aerocolonigenes, is a well-known topoisomerase (Topo) I poison. In the course of structure-activity relationship studies on rebeccamycin analogs, we have prepared a large number of indolocarbazole derivatives and have shown that, depending on the structural modifications, the cytotoxic effects may be, or not, directly correlated to DNA binding and Topo I inhibition. This suggests that if DNA binding and Topo I play a part in the biological activity of these compounds, other cellular targets might be involved. This paper reports the results of the antiproliferative activities (evaluated in the National Cancer Institute's in vitro panel of 60 tumor cell lines) and the results of a COMPARE analysis run with rebeccamycin derivatives to identify other potential biological targets for these compounds.
Collapse
Affiliation(s)
- Pascale Moreau
- Laboratoire SEESIB, Université Blaise Pascal, UMR 6504 du CNRS, Aubière, France
| | | | | | | |
Collapse
|